News >

Olaparib Plus Bevacizumab Improves PFS as Frontline Maintenance in Ovarian Cancer

Jason M. Broderick @jasoncology
Published: Wednesday, Aug 14, 2019

Jose Baselga, MD

José Baselga, MD

Combining olaparib (Lynparza) with standard bevacizumab (Avastin) significantly improved progression-free survival (PFS) compared with bevacizumab alone as frontline maintenance therapy in women with advanced ovarian cancer, regardless of BRCA status, according to topline results from the phase III PAOLA-1 trial.1

AstraZeneca and Merck (MSD), the codevelopers of olaparib, reported in a press release that the results from PAOLA-1 will be presented at an upcoming medical conference. The companies also noted that the safety and tolerability data were consistent with results previously reported for the agents.

“The positive results from the PAOLA-1 trial demonstrate a clear potential benefit of adding Lynparza to the standard-treatment bevacizumab for women with advanced ovarian cancer. Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive phase III trial for Lynparza as a first-line maintenance treatment for women with advanced ovarian cancer. We look forward to discussing the results with global health authorities as soon as possible,” José Baselga, MD, PhD, executive vice president, Oncology R&D, of AstraZeneca, stated in the press release.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x